Patients with type 2 diabetes face up to a three-fold increased risk of hip fracture, despite adequate areal bone mineral density which may underestimate fracture risk in these patients.
The objective of this study was to analyze the risk of incident vertebral and nonvertebral fracture in men with DISH.
Researchers sought to identify potential vertebral fracture and bone loss risk factors after discontinuation of denosumab therapy and initiation of other therapy.
Several studies have assessed the potentially increased rate and the management of osteoporotic and fragility fractures during the COVID-19 pandemic.
Researchers evaluated the association between osteoporosis and vertebral fragility fractures with cardiovascular calcification in patients with chronic obstructive pulmonary disease.
Researchers evaluated the association between risk for atypical fracture and duration of bisphosphonate use in women with osteoporosis.
The use of sodium-glucose transporter-2 inhibitors combined with metformin did not affect fracture risk in T2D.
In this systematic review, the study authors evaluated the current evidence on orthogeriatric care for older patients with hip fracture.
In 2018, 27.5 percent of older adults reported falling at least once in the previous year, with 10.2 percent reporting an injury from a fall.
Low hemoglobin A1c and low body mass index are associated with higher risk for bone fracture in individuals with type 2 diabetes.
